Stay updated with breaking news from Sun Pharma Q2. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The healthy earnings growth for Sun Pharma was aided by strong global specialty sales and an industry-beating performance in the domestic market even as US sales faltered sequentially.
Sun Pharma Q2 Results: Net Profit Rises 5% YoY To Rs 2,375 Crore, Sales Up 11%, its Ebitda, including other operating revenues, was up 7.5 per cent to Rs 3,179.4 crore
Operating profit, calculated as earnings before interest, taxes, depreciation, and amortization (EBITDA), for the quarter, rose nearly 8% on year to Rs 3,179.30 crore, but operating margin contracted by 91 basis points to 26.08%. Total expenses in the quarter rose to Rs 9,695 crore, from Rs 8,625 crore a year ago.
Sun Pharma reported a profit after tax of Rs 2,375 crore in the September quarter up by 5 per cent against Rs 2,262 crore in the corresponding quarter last year, , Sun Pharma q2 results, sun pharma, Sun Pharma q2, sun pharmaceutical industries, pharmaceutical market
The earnings for interest, tax, depreciation and ammortisation (EBITDA) rose 7.5% to Rs. 3179.4 crore in Q2, and EBITDA margins declined 90 basis points YoY to 26.1%. India formulation sales rose 11.1% YoY to Rs. 3843 crore in Q2FY24. India accounts for 32% of Sun Pharma sales